NCT01111045已完成2 期
A Phase 2, Double Blind, Randomized, Placebo-Controlled, Proof of Concept, Dose Finding Study of Intraarticular Bone Morphogenetic Protein (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 355
- 试验地点
- 25
- 主要终点
- Change from baseline in Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain subscale.
研究概览
简要总结
The objectives of the study are to evaluate the safety and efficacy of intraarticular BMP-7 for the treatment of osteoarthritis of the knee.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ambulatory with a diagnosis of OA of the knee with symptoms for at least 6 months and pain on the majority of days in the last 30 days. Symptoms must include knee joint pain.
- •A male or female adult age >40 years
- •female subjects of childbearing potential must have a negative serum pregnancy test during screening and a negative urine pregnancy test on the day of injection
- •Radiographic evidence of at least one tibiofemoral osteophyte and Osteoarthritis Research Society International (OARSI) Atlas joint space narrowing grade of 1 or 2 in the index knee
- •WOMAC pain score of >8 at screening and baseline
- •Able to comply with the study and give informed consent
- •Able to read, write and understand English
排除标准
- •A requirement for treatment with opioids for pain relief.
- •Unwilling to abstain from NSAIDs and/or other analgesic medications for 48 hours and acetaminophen for 24 hours prior to pain assessments during the study. Subjects taking low dose aspirin for cardiovascular health may remain on their stable dose throughout the study.
- •Using a handicap assistance device (i.e., cane, walker) >50% of the time.
- •Undergoing new physical therapy or participating in a weight loss or exercise program that has not been stable for at least 3 months prior to screening visit 1 and will not remain stable during their participation in the study.
- •History of arthroscopic or open surgery to the index knee in the past 12 months or planned surgery during study.
- •History of joint replacement surgery (index knee).
- •Received corticosteroid, short acting hyaluronic acid, or other intraarticular injections of the index knee within 3 months of screening and/or not willing to abstain from treatments for the duration of the study
- •Received long acting hyaluronic acid injection of the index knee within 6 months of screening and/or not willing to abstain from treatments for the duration of the study.
- •History in the past 10 years of reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, amyloidosis or fibromyalgia.
- •Clinical signs and symptoms of active knee infection or radiographic evidence of crystal disease other than chondrocalcinosis (i.e., gout and CPPD).
- •A history of abnormal laboratory results ≥2.5 x ULN indicative of any significant medical disease, which in the opinion of the investigator, would preclude the subjects participation in the study
- •Any of the following abnormal laboratory results during screening:
- •ALT and AST ≥2.5x ULN
- •Hemoglobin <11.5 g/dL (Female) or <13.2 g/dL (Male)
- •WBC <3500 cells/mm3
- •Lymphocyte count ≤1000 cells/mm3
- •Serum creatinine ≥1.5 x ULN
- •Platelet count below the central laboratory lower limit of normal.
- •History of malignancy in the past ten years (<10 years), with the exception of resected basal cell, squamous cell of the skin, resected cervical atypia or carcinoma in situ.
- •Significant hip pain, ipsilateral to the index knee that may interfere with assessments of index knee pain
- •Skin breakdown at the knee where the injection would take place
- •A known or clinically suspected infection with human immunodeficiency virus (HIV), or hepatitis C or B viruses
- •Participated within 3 months or will participate concurrently in another investigational drug or vaccine study
- •A history of drug or alcohol dependence or abuse in the past 3 years
- •Previous treatment with BMP-7 or any bone morphogenetic protein
- •A female with reproductive capability who is unwilling to use birth control for the duration of the study and/or intends to conceive within 12 months of dosing.
- •Other serious, non-malignant, significant, acute or chronic medical or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.
研究组 & 干预措施
Arm 1
Active Comparator
0.03 mg/ml BMP-7, single intraarticular knee injection
干预措施: Bone morphogenetic protein 7 (Drug)
Arm 2
Active Comparator
0.1 mg/ml BMP-7, single intraarticular knee injection
干预措施: Bone morphogenetic protein 7 (Drug)
Arm 3
Active Comparator
0.3 mg/ml BMP-7, single intraarticular knee injection
干预措施: Bone morphogenetic protein 7 (Drug)
Arm 4
Placebo Comparator
1 ml placebo, single intraarticular knee injection (control)
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain subscale.
时间窗: Baseline, and at 24 weeks
次要结局
未报告次要终点
研究者
研究点 (25)
Loading locations...
相似试验
已完成
2 期
Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy AdultsEscherichia InfectionNCT06692907National Institute of Allergy and Infectious Diseases (NIAID)72
尚未招募
1 期
Evaluation of Safety and Efficacy of Wharton's Jelly Compared to Hyaluronic Acid and Saline for Knee Osteoarthritis.Osteoarthritis, KneeNCT04711304BioIntegrate168
尚未招募
2 期
A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)Moderate to Severe Rheumatoid ArthritisNCT06306339ImmuneMed, Inc.60
招募中
不适用
Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.Esophageal NeoplasmsHead and Neck NeoplasmsGastrointestinal NeoplasmsDigestive System DiseasesDigestive System NeoplasmsEsophageal DiseasesNeoplasms by SiteGastrointestinal DiseasesNeoplasmsNCT06365866Taipei Veterans General Hospital, Taiwan20
已完成
3 期
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2Hepatitis C, ChronicNCT01728324Boehringer Ingelheim496